SCHEMBL4572804

SCHEMBL4572804

C#Cc1ccc(-n2cc(C(=O)OCC)c(=O)c3cnc(SC)nc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 6/20 0.42
MAPT P10636 5/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 3/20 0.41
LMNA P02545 2/20 0.40
FOS P01100 1/20 0.40
JUN P05412 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SYK P43405 2/20 0.40
MAPK1 P28482 2/20 0.38
HTT P42858 2/20 0.38
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4583739 0.89 CSF1R (0.46) CSF1RMEN1KMT2AALDH1A1MAPT
SCHEMBL3290264 0.88 ALDH1A1 (0.53) CSF1RMEN1KMT2AALDH1A1MAPT
SCHEMBL4573769 0.84 CSF1R (0.43) CSF1RMEN1KMT2AALDH1A1MAPT
SCHEMBL3289970 0.81 CSF1R (0.65) CSF1R
SCHEMBL16088471 0.81 MAPT (0.49) CSF1RMEN1KMT2AALDH1A1MAPT
SCHEMBL11582898 0.78 SMN1; SMN2 (0.53) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL4573766 0.77 CSF1R (0.46) CSF1RMEN1KMT2APOLBLMNA
SCHEMBL8802224 0.77 KMT2A (0.44) CSF1RMEN1KMT2AALDH1A1MAPT
SCHEMBL4574233 0.75 CSF1R (0.61) CSF1RPOLB
SCHEMBL3526298 0.74 TSHR (0.54) MEN1KMT2AALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-15 US disclosed
WO-2008055013-A2 5-OXO-5,8 - DIHYDRO - PYRIDO - PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE FLT3, FES, ALK CSF1R 430/4885MEN1 3558/4885KMT2A 2689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.